Literature DB >> 9442785

Surgical results of secondary glaucomas in childhood.

D K Wallace1, D A Plager, S K Snyder, A Raiesdana, E M Helveston, F D Ellis.   

Abstract

OBJECTIVE: This study aimed to describe results of glaucoma surgeries performed at one institution over the past 20 years in children with aphakia, aniridia, anterior segment dysgenesis, and other secondary glaucomas.
DESIGN: The study design was a retrospective review. PARTICIPANTS: Fifty-eight eyes of 40 patients were studied. INTERVENTION: Trabeculectomy with or without mitomycin C, Molteno implantation, goniotomy, sclerostomy, endolaser cyclophotocoagulation, and cyclocryotherapy were performed. MAIN OUTCOME MEASURES: Intraocular pressure (IOP) control, defined as complete success (IOP < or = 21 without medications) or qualified success (IOP < or = 25 without medications or IOP < or = 21 with medications) and postoperative visual acuity stability were assessed.
RESULTS: One hundred thirty surgical procedures were performed on 58 eyes of 40 patients; follow-up averaged 7.3 years. Intraocular pressure control was achieved in 40 (70%) of 57 eyes after 1 or more procedures. Intraocular pressure control and stabilization of visual acuity and optic disc appearance were achieved in 28 (51%) of 55 eyes. Five eyes had significant postoperative complications. Trabeculectomy with mitomycin C controlled IOP on last visit in 8 of 13 eyes with aphakic glaucoma.
CONCLUSIONS: Surgical intervention can control IOP and prevent visual loss in children with secondary glaucomas. In the authors' experience, a filtering procedure is the most effective treatment in aphakic glaucoma and anterior segment dysgenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9442785     DOI: 10.1016/s0161-6420(98)91519-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  19 in total

1.  Collagen type I and III synthesis by Tenon's capsule fibroblasts in culture: individual patient characteristics and response to mitomycin C, 5-fluorouracil, and ascorbic acid.

Authors:  R L Gross
Journal:  Trans Am Ophthalmol Soc       Date:  1999

2.  Baerveldt glaucoma implant in paediatric patients.

Authors:  K A van Overdam; J T H N de Faber; H G Lemij; P W T de Waard
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

3.  Early-onset glaucoma in Axenfeld-Rieger anomaly: long-term surgical results and visual outcome.

Authors:  A K Mandal; N Pehere
Journal:  Eye (Lond)       Date:  2016-04-08       Impact factor: 3.775

4.  Filtration procedures supplemented with mitomycin C in the management of childhood glaucoma.

Authors:  A Azuara-Blanco; R P Wilson; G L Spaeth; C M Schmidt; J J Augsburger
Journal:  Br J Ophthalmol       Date:  1999-02       Impact factor: 4.638

5.  Risk factors for failures of trabeculectomies performed without antimetabolites.

Authors:  H Mietz; B Raschka; G K Krieglstein
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

6.  Medical and surgical outcomes in childhood glaucoma: a population-based study.

Authors:  Elisabeth P Aponte; Nancy Diehl; Brian G Mohney
Journal:  J AAPOS       Date:  2011-06-11       Impact factor: 1.220

7.  Prognosis of primary ab externo surgery for primary congenital glaucoma.

Authors:  T S Dietlein; P C Jacobi; G K Krieglstein
Journal:  Br J Ophthalmol       Date:  1999-03       Impact factor: 4.638

8.  Goniosurgery for prevention of aniridic glaucoma.

Authors:  T C Chen; D S Walton
Journal:  Trans Am Ophthalmol Soc       Date:  1998

9.  Bilateral sporadic aniridia: review of management.

Authors:  Caroline O Adeoti; Adebimpe A Afolabi; Adeyinka A Afolabi; Adeyinka O Ashaye; Adebimpe O Ashaye; Adenike O Adeoye
Journal:  Clin Ophthalmol       Date:  2010-10-05

10.  Efficacy and safety of trabeculectomy with mitomycin C for childhood glaucoma: a study of results with long-term follow-up.

Authors:  Jair Giampani; Adriana Silva Borges-Giampani; José Carlos Eudes Carani; Ernst Werner Oltrogge; Remo Susanna
Journal:  Clinics (Sao Paulo)       Date:  2008-08       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.